This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ricoveri, W. Articles by Cappelletti, R. Search for Related Content PubMed PubMed Citation Articles by Ricoveri, W. Articles by Cappelletti, R.

Heparan Sulfate Endoglycosidase and Metastatic Potential in Murine Fibrosarcoma and Melanoma¹

Istituto di Patologia Generale, Università di Firenze, Viale G. B. Morgagni, 50, 50134 Firenze, Italy

Several fibroblast and melanoma cell lines were studied with respect to their ability to degrade heparan sulfate (HS).

The optimum pH for HS degradation by HS endoglycosidase (heparanase) for all cell lines is about 5.6, but the activity of the enzyme is still present at physiological pH.

The gel permeation analysis of degradation products revealed that heparanase cuts HS in fragments about one-seventh of their original size.

Since the optimum pH of HS endoglycosidase activity and the terminal molecular weight of degraded HS are the same in both cell lines, it is likely that fibrosarcoma and melanoma heparanases are identical enzymes.

Cell extracts and intact cells of metastatic sublines degrade HS faster than do their nonmetastatic counterparts.

The degradative activity of intact cells parallels those of cell extracts, but at a much lower level; moreover, conditioned media do not appreciably degrade HS, suggesting that heparanase is scarcely released into the medium; thus, considering the differences in degradative activity between cell extracts and intact cells or conditioned medium and the occurrence of cell lysis in a tumor in vivo, we suggest that the measure of degradative activity of intact cells in vitro is not indicative of a relationship to metastasis. The total cellular content of lytic enzymes could represent the real metastatic potential of proliferating cells, but it is also necessary to find an in vitro model better representing the behavior of neoplastic cells in vivo.

¹ This work was supported by a grant of the Italian Consiglio Nazionale delle Ricerche Special Project, Control of Neoplastic Growth, Co.N 83.0075B.96 and by a grant of the Ministero della Pubblica Istruzione 60%, 1983.

² To whom requests for reprints should be addressed.

Received 10/ 5/84. Revised 2/28/86. Accepted 4/16/86.

This article has been cited by other articles:

				A. Zetser, Y. Bashenko, H.-Q. Miao, I. Vlodavsky, and N. Ilan Heparanase Affects Adhesive and Tumorigenic Potential of Human Glioma Cells Cancer Res., November 15, 2003; 63(22): 7733 - 7741. [Abstract] [Full Text] [PDF]

				A. Koliopanos, H. Friess, J. Kleeff, X. Shi, Q. Liao, I. Pecker, I. Vlodavsky, A. Zimmermann, and M. W. Buchler Heparanase Expression in Primary and Metastatic Pancreatic Cancer Cancer Res., June 1, 2001; 61(12): 4655 - 4659. [Abstract] [Full Text] [PDF]

				O. N. El-Assal, A. Yamanoi, T. Ono, H. Kohno, and N. Nagasue The Clinicopathological Significance of Heparanase and Basic Fibroblast Growth Factor Expressions in Hepatocellular Carcinoma Clin. Cancer Res., May 1, 2001; 7(5): 1299 - 1305. [Abstract] [Full Text]